Press Room
Duchesnay Inc. is seeking Health Canada approval for a segesterone acetate/ethinyl estradiol contraceptive vaginal system, a new option for women.
Slynd® (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
The CEO of Duchesnay Pharmaceutical Groupe, Éric Gervais, shared his thoughts on the future of the life sciences industry with Investment Reports.
